• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Establishment of DNA-based diagnosis and elucidation of molecular mechanisms for response and loss of response to infliximab at short or long period of treatment against Crohn's disease

Research Project

Project/Area Number 16K08912
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Applied pharmacology
Research InstitutionNagasaki University

Principal Investigator

TSUKAMOTO Kazuhiro  長崎大学, 医歯薬学総合研究科(薬学系), 教授 (30253305)

Project Period (FY) 2016-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywordsクローン病 / インフリキシマブ / 薬剤応答性遺伝子 / 治療感受性の機序解明 / 治療抵抗性の機序解明 / 遺伝子診断 / ゲノム創薬 / 治療効果消失の機序解明 / 治療感受性遺伝子 / 治療抵抗性遺伝子 / 腫瘍壊死因子シグナル共有経路 / P2RX7シグナル経路 / レミケード / 効果予測の遺伝子診断法
Outline of Final Research Achievements

Infliximab (IFX) is a monoclonal antibody exerting the therapeutic effect for Crohn’s disease (CD). We examined an association study of 162 tag single nucleotide polymorphisms in 32 candidate genes with response to IFX at the 10-weeks or 1-year period of treatment for Japanese 127 CD patients, identifying 6 and 9 IFX-responsibility genes at the 10-weeks and 1-year period, respectively.
Multivariate analyses and genetic tests revealed that the best combination of polymorphisms of TRAF2 and TLR2 is useful as a biomarker for identifying responders to IFX at the 10-weeks period of treatment. Likewise, a combination of polymorphisms of CD40, P2RX7, and CASP1 is most suitable for identifying responders at the 1-year period of treatment against CD patients.

Academic Significance and Societal Importance of the Research Achievements

クローン病患者に対するインフリキシマブ治療において,投与開始10週後も治療効果が持続する患者と治療効果が消失する患者では,どのような遺伝的背景であるかを解明できた。同様に,投与開始1年後の治療効果についても解明できた。さらに,10週後と1年後に関与する遺伝子は異なり,病態の分子機序が異なっていた。
治療効果に関与していた遺伝子をバイオマーカーに用いた遺伝子診断法を開発した。インフリキシマブを投与する前にクローン病患者の10週後と1年後の治療効果あるいは治療効果消失が予測でき,個々の患者に最適の治療戦略を立案できる材料を提供できたことは,今後の個別化治療につながる成果であった。

Report

(5 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • 2016 Research-status Report
  • Research Products

    (15 results)

All 2020 2019 2018 2017 2016 Other

All Journal Article (4 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 4 results,  Open Access: 2 results,  Acknowledgement Compliant: 1 results) Presentation (10 results) (of which Int'l Joint Research: 3 results) Remarks (1 results)

  • [Journal Article] The JAK/STAT3 and NF-kappa B signaling pathways regulate cancer stem cell properties in anaplastic thyroid cancer cells2019

    • Author(s)
      K. Shiraiwa, M. Mitsutake, Y. Nakazawa, T. Ogi, K. Suzuki, V. Saenko, K. Umezawa, S. Yamashita, K. Tsukamoto
    • Journal Title

      Thyroid

      Volume: in press Issue: 5 Pages: 674-682

    • DOI

      10.1089/thy.2018.0212

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Genetic variants of SMAD2/3/4 are associated with susceptibility to ulcerative colitis in a Japanese genetic background2019

    • Author(s)
      Yamashita A, Inamine T, Suzuki S, Fukuda S, Unoike M, Kawafuchi Y, Machida H, Isomoto H, Nakao K, Tsukamoto K
    • Journal Title

      Immunol Lett

      Volume: 207 Pages: 64-72

    • DOI

      10.1016/j.imlet.2019.01.007

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Blockade of analgesic effects following systemic administration of N-methyl-kyotorphin, NMYR and arginine in mice deficient of preproenkephalin or proopiomelanocortin gene2018

    • Author(s)
      Neyama H, Hamada Y, Tsukahara R, Narita M, Tsukamoto K, Ueda H
    • Journal Title

      Peptides

      Volume: 107 Pages: 10-16

    • DOI

      10.1016/j.peptides.2018.06.010

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] The evidence of genetic polymorphisms of genes involved in the P2RX7 signaling pathway as predictive biomarkers for response and loss of response to infliximab against Crohn's disease2016

    • Author(s)
      Araki C, Yoshimura M, Fukumitsu Y, Ma S, Ishida T, Urabe S, Matsushima K, Honda T, Uehara R, Fukuda Y, Takeshima F, Higuchi N, Isomoto H, Nakao K, Tsukamoto K
    • Journal Title

      Integrative Molecular Medicine

      Volume: 3 Issue: 6 Pages: 1-15

    • DOI

      10.15761/imm.1000262

    • Related Report
      2016 Research-status Report
    • Peer Reviewed / Open Access / Acknowledgement Compliant
  • [Presentation] SMAD2多型が潰瘍性大腸炎の発症に関与するメカニズムの解明2020

    • Author(s)
      岡田 晃,田添優奈,本田依子,稲嶺達夫,磯本 一,塚元和弘
    • Organizer
      日本薬学会第140年会
    • Related Report
      2019 Annual Research Report
  • [Presentation] がん細胞におけるAXL亜型の発現と薬剤耐性における潜在的役割2020

    • Author(s)
      稲嶺達夫,大葉春奈,河野紗羅,小畑京佑,上野まどか,山口博之,迎 寛,塚元和弘
    • Organizer
      日本薬学会第140年会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 非アルコール性脂肪性肝疾患を誘導する高脂肪食による腸管分泌型IgAの変動2020

    • Author(s)
      照井海人,豊永ちなみ,松浦真由子,坂本裕介,石橋潤大,渡邊佑輔,塚元和弘,稲嶺達夫
    • Organizer
      日本薬学会第140年会
    • Related Report
      2019 Annual Research Report
  • [Presentation] PLATとANXA2の多型は抗うつ薬治療抵抗性に関与する2019

    • Author(s)
      谷口 彩,西園美紀,伊地知俊介,稲嶺達夫,塚元和弘
    • Organizer
      日本薬学会第139年会
    • Related Report
      2018 Research-status Report
  • [Presentation] RGS2はH. pylori陽性の萎縮性胃炎の進行に関与する2019

    • Author(s)
      本田依子,田添優奈,稲嶺達夫,福田大輔,磯本 一,塚元和弘
    • Organizer
      日本薬学会第139年会
    • Related Report
      2018 Research-status Report
  • [Presentation] ATG16L1 and ATG12 are involved in the pathogenesis of gastric mucosal atrophy in Japanese patients2018

    • Author(s)
      Obata K, Ueda H, Hirado M, Taira M, Inamine T, Fukuda D, Nakao K, Isomoto H, Tsukamoto K
    • Organizer
      68th American Society of Human Genetics Annual Meeting 2018
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] Association between hepatic CYP7A1 activity and PGC-1α polymorphism2018

    • Author(s)
      Inamine T, Makimoto A, Ohyama K, Tsukamoto K
    • Organizer
      68th American Society of Human Genetics Annual Meeting 2018
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] TNFRSF1Aのrs2284344多型はインフリキシマブ治療抵抗性に関与する2018

    • Author(s)
      田添優奈,谷口隼輔,稲嶺達夫,近藤新二,磯本 一,塚元和弘
    • Organizer
      日本薬学会第137年会
    • Related Report
      2017 Research-status Report
  • [Presentation] Associations between a polymorphism of the gene encoding the Toll like receptor and response to infliximab in Japanese patients with Crohn’s disease2017

    • Author(s)
      Ma S, Fukumitsu Y, Noma Y, Inamine T, Kondo S, Urabe S, Matsushima K, Uehara R, Honda T, Machida H, Yamaguchi N, Ohnita K, Takeshima F, Isomoto H, Nakao K, Tsukamoto K
    • Organizer
      67th American Society of Human Genetics Annual Meeting
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research
  • [Presentation] IL-1R1受容体の下流シグナル経路はクローン病患者におけるインフリキシマブ長期治療効果に関与する2017

    • Author(s)
      野間友梨恵,吉村 萌,福満悠史,馬 碩,稲嶺達夫,近藤新二,磯本 一,塚元和弘
    • Organizer
      第34回日本薬学会九州支部大会
    • Related Report
      2017 Research-status Report
  • [Remarks] 長崎大学大学院医歯薬学総合研究科・薬物治療学分野

    • URL

      http://www.ph.nagasaki-u.ac.jp/lab/treat/works-j.html

    • Related Report
      2019 Annual Research Report 2018 Research-status Report

URL: 

Published: 2016-04-21   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi